Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX) [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
evidence into Recursion's tech-enabled drug discovery and development platform, aiming to improve clinical trial design, site selection, and decision-making. Recursion also disclosed a leadership transition, with experienced oncology drug developer Vicki Goodman, M.D., set to become Chief Medical Officer in April 2026 as David Mauro, M.D., Ph.D. steps down after roughly three years, underscoring the company's focus on late-stage clinical and oncology expertise. We'll now examine how the expanded Citeline partnership, particularly its real-world data integration, could reshape Recursion's investment narrative and risk profile. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. Recursion Pharmaceuticals Investment Narrative Recap To own Recursion, you have to believe its AI-driven platform and partnerships can eventually turn today's sizeable losses and cash burn into a sustainable drug pipeline. The Citeline expa
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion to Participate in Upcoming Investor ConferencesGlobeNewswire
- Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform [Yahoo! Finance]Yahoo! Finance
- 1 Beaten-Down AI Stock to Buy and 1 to Avoid [Yahoo! Finance]Yahoo! Finance
- Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech PlatformGlobeNewswire
- 2 AI Healthcare Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- RXRX's page on the SEC website